ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Oxaliplatin Regimen May Beat Standard For Advanced Colorectal Cancer, NCI Says

May 3, 2002

NCI Advisory Group, Other Cancer Meetings For May, June

April 30, 1976

New NCAB Weak In Grant Reviews, Confused By Issues

December 10, 1982

Finasteride Improved Performance Of PSA In Prostate Cancer Prevention Trial

August 25, 2006

NCI Study Tests Method For Biomarker Validation

July 24, 2009

Page 2: The Debate Over Brigham’s Containment Bag Study

November 21, 2014